Additionally, growth factor pathways, such as the IGF-1R and EGFR pathways, can activate AR in a ligand-independent manner, and enzymes such as CYP17A1 or AKR1C3 facilitate intratumoral androgen synthesis, providing an alternative route for tumor cells to circumvent low-androgen conditions. This evidence concerns the gene AR and neoplasm.